Search results
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
Reuters via Yahoo Canada News· 42 minutes ago(Reuters) -The European Union's drugs regulator has rejected Eisai and Biogen's breakthrough...
Biogen and Sage to scrap neurological disorder drug development after trial failure
Reuters via Yahoo Canada News· 2 days agoShares of Cambridge, Massachusetts-based Sage Therapeutics slumped 27% in premarket trading. The...
Is Biogen (BIIB) an Underappreciated Stock?
Insider Monkey via Yahoo Finance Canada· 2 days agoPatient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” second quarter 2024 investor letter. A...
Japan's Eisai eyes blood test for Alzheimer's drug eligibility
Nikkei Asian Review· 14 hours agoJapanese pharmaceutical company Eisai is developing a blood test to determine whether patients with...
Health Care: Q2 lobbying boost
Axios· 3 days agoAn affiliated company also named in the legislation, WuXi Biologics, spent $125,000 in Q2. Among the big Q2 spenders listing the Biosecure Act as an issue were Amgen ($2.7 million),
Sage Shares Fall After Drug Fails in Essential Tremor Study
Bloomberg· 2 days agoSage Therapeutics Inc. plunged after a mid-stage study of its drug to treat essential tremor failed,...
Global biosimilar market estimated to reach a size of $43.8 billion by the end of 2024
BioPharma-Reporter· 2 days agoThe biosimilars market is rapidly growing as global demand for biosimilars continues to grow....
Living Security Makes Its Human Risk Management Conference 2024 Available on Demand
Digital Journal· 3 days agoAUSTIN, TX / ACCESSWIRE / July 23, 2024 / Nearly two dozen experts on the front lines of cybersecurity provided their insight and advice at Living Security's third annual Human Risk Management ...